Skip to main content

In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr mice

Publication ,  Journal Article
Xu, XL; Blinder, L; Shen, JK; Gong, HH; Finnegan, A; Williams, JW; Chong, ASF
Published in: JOURNAL OF IMMUNOLOGY
1997

Duke Scholars

Published In

JOURNAL OF IMMUNOLOGY

ISSN

0022-1767

Publication Date

1997

Volume

159

Issue

1

Start / End Page

167 / 174

Related Subject Headings

  • Immunology
  • 3204 Immunology
  • 3101 Biochemistry and cell biology
  • 1107 Immunology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Xu, X. L., Blinder, L., Shen, J. K., Gong, H. H., Finnegan, A., Williams, J. W., & Chong, A. S. F. (1997). In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr mice. JOURNAL OF IMMUNOLOGY, 159(1), 167–174.
Xu, X. L., L. Blinder, J. K. Shen, H. H. Gong, A. Finnegan, J. W. Williams, and A. S. F. Chong. “In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr mice.” JOURNAL OF IMMUNOLOGY 159, no. 1 (1997): 167–74.
Xu XL, Blinder L, Shen JK, Gong HH, Finnegan A, Williams JW, et al. In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr mice. JOURNAL OF IMMUNOLOGY. 1997;159(1):167–74.
Xu, X. L., et al. “In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr mice.” JOURNAL OF IMMUNOLOGY, vol. 159, no. 1, 1997, pp. 167–74.
Xu XL, Blinder L, Shen JK, Gong HH, Finnegan A, Williams JW, Chong ASF. In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr mice. JOURNAL OF IMMUNOLOGY. 1997;159(1):167–174.

Published In

JOURNAL OF IMMUNOLOGY

ISSN

0022-1767

Publication Date

1997

Volume

159

Issue

1

Start / End Page

167 / 174

Related Subject Headings

  • Immunology
  • 3204 Immunology
  • 3101 Biochemistry and cell biology
  • 1107 Immunology